Vaccination from chickenpox "Varilrix"

The first vaccination against varicella was created and approved for use in Japan in 1974. Vaccine production is carried out using a live attenuated strain.

After receiving positive results in terms of effectiveness and safety, as well as the ratio of development costs, chickenpox vaccination to adults and children has been included in immunization programs in some industrialized countries. Today, the mass use of the vaccine is quite common.

In Russia in 2008, the first vaccine for chickenpox was registered. The vaccine was called "Varilrix". Since 2009, this vaccine has been included in regional immunization programs.

It should be said that chickenpox vaccination is now used in more than 92 countries around the world, including in the UK, Canada, Germany, France, Spain and Italy. The vaccine has been registered in some Baltic countries. Since the first registration and to this day around the world, the chickenpox vaccine has been produced about eleven million times. The effectiveness and safety of the vaccine "Varilrix" has been proven in the clinical trials that have been carried out in many countries around the world. This chickenpox vaccine fully meets all the requirements of WHO.

Vaccination is allowed for use in adults and children older than one year. Since 2009, the vaccine is included in the regional immunization schedule for epidemiological indications in Moscow.

It should be noted that in the first place, chickenpox vaccination is used in people at risk. These include, in particular, those suffering from severe chronic diseases, patients with leukemia, patients receiving radiotherapy and immunosuppressants, as well as those for whom organ transplantation is planned .

It is necessary to say that the immunization of persons at risk is performed in the absence of symptoms that would indicate a deficiency in cellular immunity and in accordance with the results of a clinical blood test.

Among the temporary contraindications for vaccination should be noted infectious pathologies, including acute current, as well as exacerbation of chronic pathologies. In such cases, vaccination from chickenpox is postponed until complete recovery or is carried out outside the exacerbation according to medical indications.

Contraindications to immunization include severe immunodeficiency, which has developed as a result of lymphoma, leukemia, HIV infection, the use of high doses of corticosteroids and immunosuppressants.

Vaccination is not carried out by pregnant and lactating women. Vaccination from chickenpox "Varilrix" is not administered to patients prone to allergic reactions to the components of the drug, as well as having allergic reactions in past administrations.

As observations show, the introduction of the vaccine "Varilrix" contributes to the development of persistent immunity. In children up to the age of twelve, the effectiveness of immunization averages about ninety eight percent. In persons over thirteen years, the protective properties of antibodies are estimated to be almost one hundred percent.